Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 4/2007

01.08.2007 | Original Paper

Unlicensed and off-label use of medicines at a neonatology clinic in Italy

verfasst von: Maria Dell’Aera, Anna Rita Gasbarro, Margherita Padovano, Nicola Laforgia, Donatella Capodiferro, Biagio Solarino, Roberto Quaranta, Alessandro S. Dell’Erba

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 4/2007

Einloggen, um Zugang zu erhalten

Abstract

Objective

Many drugs used for children are not licensed or are used off-label. An increased risk of medication errors and unexpected adverse drug reactions (ADR) associated with off-label and unlicensed drug prescription has been reported. This risk increases in the newborn, who are more likely to be predisposed to an ADR due to their physiological immaturity. The objective of this study was to describe the use of unlicensed or off-label drugs in a Neonatal Intensive Care Unit (NICU).

Methods

All drugs prescribed to newborn admitted to the Neonatology Unit of Bari University Hospital, from July 1st to August 31st in 2004 were recorded.

Main outcome measures

All the drugs prescribed were analysed with regard to their license status, then the licensed drugs were compared to the indications, dose, route of administration, duration of treatment, contraindications and warnings specified in the summary of product characteristics of the marketing authorization.

Results

Data were collected on 176 prescriptions for 61 different drugs given to 34 newborns. Drugs were licensed in 88% and unlicensed in 12% of cases. About the licensed drugs, in 37.5% medicines were used following the terms of the marketing authorization, in 22.7% of cases medicines were used in an off-label manner as they contained no information for paediatric use in the marketing authorization and in 27.8% of cases medicines were licensed for paediatric use, but they were used off-label with regard to age, dose, route of administration and duration of treatment.

Conclusions

Despite European and American initiatives aiming to promote greater awareness and research in the paediatric population, these data demonstrate that there is still a high percentage of unlicensed or off-label drugs use in neonatology, underlining the need to stimulate scientific data collection by means of experimental studies or outcome research.
Literatur
1.
2.
Zurück zum Zitat Kauffman RE. Status of drug approval processes and regulation of medications for children. Curr Opin Pediatr 1995;7:195–8.PubMedCrossRef Kauffman RE. Status of drug approval processes and regulation of medications for children. Curr Opin Pediatr 1995;7:195–8.PubMedCrossRef
4.
Zurück zum Zitat Avenel S, Bomkratz A, Dasssieu G, Janaud JC, Danan C. The incidence of prescriptions without marketing product licence in a neonatal intensive care unit. Arch Pediatr 2000;7:143–7.PubMedCrossRef Avenel S, Bomkratz A, Dasssieu G, Janaud JC, Danan C. The incidence of prescriptions without marketing product licence in a neonatal intensive care unit. Arch Pediatr 2000;7:143–7.PubMedCrossRef
5.
Zurück zum Zitat O’Donnell CP, Stone RS, Morley CJ. Unlicensed and Off-label drug use in an australian neonatal intensive care unit. Pediatrics 2002;110(5):e52.PubMedCrossRef O’Donnell CP, Stone RS, Morley CJ. Unlicensed and Off-label drug use in an australian neonatal intensive care unit. Pediatrics 2002;110(5):e52.PubMedCrossRef
6.
Zurück zum Zitat ‘t Jong GW, Vulto AG, de Hoog M, Schimmel KJ, Tibboel D, van den Anker JN. A survey of the use of off-label and unlicensed drugs in a Dutch children’s hospital. Pediatrics 2001;108:1089–93.PubMedCrossRef ‘t Jong GW, Vulto AG, de Hoog M, Schimmel KJ, Tibboel D, van den Anker JN. A survey of the use of off-label and unlicensed drugs in a Dutch children’s hospital. Pediatrics 2001;108:1089–93.PubMedCrossRef
7.
Zurück zum Zitat ‘t Jong GW, Vulto AG, de Hoog M, Schimmel KJ, Tibboel D, van den Anker JN. Unapproved and off-label use of drugs in a children’s hospital. New Engl J Med 2000;343:1125.PubMedCrossRef ‘t Jong GW, Vulto AG, de Hoog M, Schimmel KJ, Tibboel D, van den Anker JN. Unapproved and off-label use of drugs in a children’s hospital. New Engl J Med 2000;343:1125.PubMedCrossRef
8.
Zurück zum Zitat Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, et al. Survey of unlicensed and off-label drug use in European countries. BMJ 2000;320(7227):79–82.PubMedCrossRef Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, et al. Survey of unlicensed and off-label drug use in European countries. BMJ 2000;320(7227):79–82.PubMedCrossRef
9.
Zurück zum Zitat McIntyre J, Conroy S, Avery A, Corus H, Choonara I. Unlicensed and off-label prescribing of drugs in general practice. Arch Dis Child 2000;83:498–501.PubMedCrossRef McIntyre J, Conroy S, Avery A, Corus H, Choonara I. Unlicensed and off-label prescribing of drugs in general practice. Arch Dis Child 2000;83:498–501.PubMedCrossRef
10.
Zurück zum Zitat Ekins-Daukes S, Helms PJ, Simpson CR, Taylor MW, McLay JS. Off-label prescribing to children in primary care: retrospective observational study. Eur J Clin Pharmacol 2004;60(5):349–53.PubMedCrossRef Ekins-Daukes S, Helms PJ, Simpson CR, Taylor MW, McLay JS. Off-label prescribing to children in primary care: retrospective observational study. Eur J Clin Pharmacol 2004;60(5):349–53.PubMedCrossRef
11.
Zurück zum Zitat Pandolfini C, Impicciatore P, Provasi D, Rocchi F, Campi R, Bonati M, The Italian Paediatric Off-label Collaborative Group. Off-label use of drugs in Italy: a prospective, observational and multicentre study. Acta Pediatr 2002;91:339–47.CrossRef Pandolfini C, Impicciatore P, Provasi D, Rocchi F, Campi R, Bonati M, The Italian Paediatric Off-label Collaborative Group. Off-label use of drugs in Italy: a prospective, observational and multicentre study. Acta Pediatr 2002;91:339–47.CrossRef
12.
Zurück zum Zitat Cuzzolin L, Zaccaron A, Fanos V, et al. Unlicensed and off-label uses of drugs in paediatrics: a review of the literature. Fundam Clin Pharmacol 2003;17(1):125–31.PubMedCrossRef Cuzzolin L, Zaccaron A, Fanos V, et al. Unlicensed and off-label uses of drugs in paediatrics: a review of the literature. Fundam Clin Pharmacol 2003;17(1):125–31.PubMedCrossRef
13.
Zurück zum Zitat Conroy S, McIntyre J, Choonara I. Unlicensed and off-label drug use in neonates. Arch Dis Child Fetal Neonatal 1999;80:F142–5.CrossRef Conroy S, McIntyre J, Choonara I. Unlicensed and off-label drug use in neonates. Arch Dis Child Fetal Neonatal 1999;80:F142–5.CrossRef
14.
Zurück zum Zitat US Food and Drug Administration. Class labeling for intranasal and orally inhaled corticosteroid containing drug products regarding the potential for growth suppression in children. Division of Pulmonary Drug Product. Rockville, MD: US Food and Drug Administration; November 9,1998. Talk Paper. Available at://www.fda.gov/cder/news/cs_label.htm. US Food and Drug Administration. Class labeling for intranasal and orally inhaled corticosteroid containing drug products regarding the potential for growth suppression in children. Division of Pulmonary Drug Product. Rockville, MD: US Food and Drug Administration; November 9,1998. Talk Paper. Available at://www.fda.gov/cder/news/cs_label.htm.
15.
Zurück zum Zitat ICH Topic E11: Clinical investigation of medicinal products in the paediatric population. European Agency for the Evaluation of Medicinal products, 2001. ICH Topic E11: Clinical investigation of medicinal products in the paediatric population. European Agency for the Evaluation of Medicinal products, 2001.
16.
Zurück zum Zitat Regulations requiring manufactures to assess the safety and effectiveness of new drugs and biological products in paediatric patients: final rule. Federal register 1998:66631–73. Regulations requiring manufactures to assess the safety and effectiveness of new drugs and biological products in paediatric patients: final rule. Federal register 1998:66631–73.
17.
Zurück zum Zitat 10th Congress of the United States of America. Best pharmaceuticals for children Act, S.1789 109. 10th Congress of the United States of America. Best pharmaceuticals for children Act, S.1789 109.
18.
Zurück zum Zitat European Agency for the evaluation of Medicinal Products. Note for guidance on clinical investigation of medical products in children. London: European Agency for the Evaluation of Medicinal products, 1997. European Agency for the evaluation of Medicinal Products. Note for guidance on clinical investigation of medical products in children. London: European Agency for the Evaluation of Medicinal products, 1997.
19.
Zurück zum Zitat CINECA—Society interuniversity. Progetto ARNO–Paediatrics, Report 2004. Bologna, Italy: Centauro s.r.l.;2005. ISBN 88-85980-46-5. CINECA—Society interuniversity. Progetto ARNO–Paediatrics, Report 2004. Bologna, Italy: Centauro s.r.l.;2005. ISBN 88-85980-46-5.
20.
Zurück zum Zitat Official Gazette no. 227 29th of September 2005. AIFA: The independent research of drugs financed by AIFA. Official Gazette no. 227 29th of September 2005. AIFA: The independent research of drugs financed by AIFA.
21.
Zurück zum Zitat Improving children’s medicines: EU reaches final agreement. IP/06/715; June 01 2006. Improving children’s medicines: EU reaches final agreement. IP/06/715; June 01 2006.
Metadaten
Titel
Unlicensed and off-label use of medicines at a neonatology clinic in Italy
verfasst von
Maria Dell’Aera
Anna Rita Gasbarro
Margherita Padovano
Nicola Laforgia
Donatella Capodiferro
Biagio Solarino
Roberto Quaranta
Alessandro S. Dell’Erba
Publikationsdatum
01.08.2007
Verlag
Kluwer Academic Publishers
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 4/2007
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-006-9081-z

Weitere Artikel der Ausgabe 4/2007

International Journal of Clinical Pharmacy 4/2007 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

CKD bei Diabetes: Neuheiten und Zukunftsaussichten

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Jeder Mensch mit Diabetes muss auf eine chronische Nierenerkrankung gescreent werden – diese neue Empfehlung spricht die KDIGO aus. Die Therapie erfolgt individuell und je nach Szenario mit verschiedenen Substanzklassen. Künftig kommt wahrscheinlich, neben RAS-Hemmung, SGLT2-Inhibition und nsMRA, eine vierte Therapiesäule hinzu.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.